A new study reveals that more than one-third of all amyotrophic lateral sclerosis (ALS) cases might be tied to genetics.
Research projects are top of the list, the organization announces.
Projects focus on stopping disease progression, restoring lost function in patients, and eliminating MS completely.
Dosing with ISIS-SMN Rx is scheduled to begin within weeks.
Dosing with ISIS-SMN Rx is scheduled to begin within weeks.